Accendra Health named Gardner-Smith CEO as Accendra Health stock fell 2.44 percent

Published on 10/08/2026 at 17:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue excluding a payer grew 2.00 percent. Accendra Health stock costs EUR 0.40 on October 8, 2026 after EUR 0.41.

Key points in brief

Accendra Health named Kenneth Gardner-Smith as its next CEO on September 17, 2026.
Second-quarter revenue excluding a commercial payer impact grew 2.00 percent, while full-year revenue guidance was USD 2.45 billion to USD 2.55 billion.
The Lang & Schwarz quote was EUR 0.40 on October 8, 2026, down 2.44 percent from EUR 0.41.
Accendra Health's next reporting date is scheduled for November 4, 2026.

ACH, US6907321029, Illustration mit AI erstellt.

Accendra Health named Kenneth Gardner-Smith as its next chief executive on September 17, 2026, while Accendra Health stock fell 2.44 percent in the October 8, 2026 Lang & Schwarz quote. The filing also disclosed a USD 1.00 million annual base salary and a target annual equity award valued at USD 6.00 million for Gardner-Smith.

Leadership change carries a price

According to the SEC on September 17, 2026, Gardner-Smith was expected to assume the role early in the fourth quarter and succeed Edward A. Pesicka, who had announced his retirement. The filing also named Scott Lloyd as chief commercial officer effective October 5, 2026.

The transition arrives as the company works through payer collection issues, cost reductions and a balance-sheet reset. The financial terms make the leadership change measurable, but the operating results remain the larger test for the new management team.

Q2 growth stayed selective

In its second-quarter call on August 10, 2026, Fortune reported that revenue excluding the impact of a commercial payer grew 2.00 percent in the second quarter of 2026. Sleep revenue grew 5.50 percent on a like-for-like basis, while diabetes grew 4.00 percent year over year.

The same call carried revised full-year 2026 guidance of USD 2.45 billion to USD 2.55 billion for revenue and USD 300.00 million to USD 320.00 million for adjusted EBITDA. The company also said payer collection effects reduced revenue and adjusted EBITDA by USD 10.00 million in the second quarter and USD 20.00 million in the first half of 2026.

What does the reset mean for cash flow?

Accendra Health said total debt stood at USD 1.72 billion after its June 2026 balance-sheet optimization, down by almost USD 400.00 million from the end of March, according to Fortune. Management expects the fourth quarter of 2026 to be stronger than the third quarter, making collections and cost execution key indicators for the revised outlook.

Three milestones frame the change

On January 2, 2026, the company began trading under the ACH ticker after changing its name from Owens & Minor, according to Accendra Health. On August 10, 2026, second-quarter revenue excluding the payer impact grew 2.00 percent and full-year adjusted EBITDA guidance stood at USD 300.00 million to USD 320.00 million, as Fortune reported. On September 17, 2026, Accendra Health named Gardner-Smith as its next CEO with a USD 1.00 million base salary, according to the SEC.

Next reporting date is November 4

AInvest reported that Accendra Health's next earnings release is scheduled for November 4, 2026, covering the third quarter of 2026. That date puts the revised revenue range and the USD 300.00 million to USD 320.00 million adjusted EBITDA outlook against the company's next operating update.

ACH quote remains under pressure

Accendra Health was trading at EUR 0.40 at Lang & Schwarz on October 8, 2026 at 5:11 p.m. CEST, down 2.44 percent versus the prior close of EUR 0.41 on October 7, 2026. The primary-exchange quote was USD 0.45 on the NYSE at 11:20 a.m. EDT on October 8, 2026, with a USD 0.44 to USD 5.60 52-week range and a USD 34.1 million market capitalization.

The further course of trading is shown by the continuously updated real-time quote of Accendra Health stock.